MAPT and Mental deterioration: This is supported by recent data showing that tau-PET outperforms plasma p-tau217 in predicting cognitive decline in symptomatic individuals50 but is not significantly higher than plasma p-tau217 in Aβ-negative and Aβ-positive cognitively unimpaired individuals44.